115 related articles for article (PubMed ID: 30521945)
1. Characterization of a dextran-budesonide prodrug for inhalation therapy.
Waters RC; Hochhaus G
Eur J Pharm Sci; 2019 Mar; 129():58-67. PubMed ID: 30521945
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis.
Varshosaz J; Emami J; Tavakoli N; Fassihi A; Minaiyan M; Ahmadi F; Dorkoosh F
Int J Pharm; 2009 Jan; 365(1-2):69-76. PubMed ID: 18804521
[TBL] [Abstract][Full Text] [Related]
3. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols.
Nurbaeti SN; Brillault J; Tewes F; Olivier JC
Eur J Pharm Sci; 2019 Oct; 138():105028. PubMed ID: 31377132
[TBL] [Abstract][Full Text] [Related]
5. Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery.
Wang Z; Gupta SK; Meenach SA
Int J Pharm; 2017 Jun; 525(1):264-274. PubMed ID: 28450166
[TBL] [Abstract][Full Text] [Related]
6. Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.
Dufour G; Bigazzi W; Wong N; Boschini F; de Tullio P; Piel G; Cataldo D; Evrard B
Int J Pharm; 2015 Nov; 495(2):869-78. PubMed ID: 26410753
[TBL] [Abstract][Full Text] [Related]
7. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
Varshosaz J; Emami J; Ahmadi F; Tavakoli N; Minaiyan M; Fassihi A; Mahzouni P; Dorkoosh F
J Drug Target; 2011 Feb; 19(2):140-53. PubMed ID: 20429772
[TBL] [Abstract][Full Text] [Related]
8. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
9. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
10. Conception, preparation and properties of functional carrier particles for pulmonary drug delivery.
Odziomek M; Sosnowski TR; Gradoń L
Int J Pharm; 2012 Aug; 433(1-2):51-9. PubMed ID: 22580211
[TBL] [Abstract][Full Text] [Related]
11. Large porous particles for respiratory drug delivery. Glycine-based formulations.
Ogienko AG; Bogdanova EG; Trofimov NA; Myz SA; Ogienko AA; Kolesov BA; Yunoshev AS; Zubikov NV; Manakov AY; Boldyrev VV; Boldyreva EV
Eur J Pharm Sci; 2017 Dec; 110():148-156. PubMed ID: 28479348
[TBL] [Abstract][Full Text] [Related]
12. [Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].
Liang ZL; Wang XH; Ni R; Zhang L; Muenster U; Mao SR
Yao Xue Xue Bao; 2015 Sep; 50(9):1180-5. PubMed ID: 26757557
[TBL] [Abstract][Full Text] [Related]
13. Development of porous particles using dextran as an excipient for enhanced deep lung delivery of rifampicin.
Kadota K; Yanagawa Y; Tachikawa T; Deki Y; Uchiyama H; Shirakawa Y; Tozuka Y
Int J Pharm; 2019 Jan; 555():280-290. PubMed ID: 30471373
[TBL] [Abstract][Full Text] [Related]
14. Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy.
Leng D; Kissi EO; Löbmann K; Thanki K; Fattal E; Rades T; Foged C; Yang M
AAPS PharmSciTech; 2019 Mar; 20(3):137. PubMed ID: 30847607
[TBL] [Abstract][Full Text] [Related]
15. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
[TBL] [Abstract][Full Text] [Related]
16. Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10.
Kuehl PJ; Cherrington A; Dobry DE; Edgerton D; Friesen DT; Hobbs C; Leach CL; Murri B; Neal D; Lyon DK; Vodak DT; Reed MD
AAPS PharmSciTech; 2014 Dec; 15(6):1545-50. PubMed ID: 25106135
[TBL] [Abstract][Full Text] [Related]
17. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats.
Varshosaz J; Emami J; Fassihi A; Tavakoli N; Minaiyan M; Ahmadi F; Mahzouni P; Dorkoosh F
Int J Colorectal Dis; 2010 Oct; 25(10):1159-65. PubMed ID: 20669022
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.
Ahmadi F; Varshosaz J; Emami J; Tavakoli N; Minaiyan M; Mahzouni P; Dorkoosh F
Drug Deliv; 2011 Feb; 18(2):122-30. PubMed ID: 20954795
[TBL] [Abstract][Full Text] [Related]
20. Development of budesonide nanocluster dry powder aerosols: processing.
El-Gendy N; Selvam P; Soni P; Berkland C
J Pharm Sci; 2012 Sep; 101(9):3425-33. PubMed ID: 22539360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
